Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines
PLOS Pathogens · 08.07.2024 · 20 (7) · e1012220
DOI: 10.1371/journal.ppat.1012220 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 08.07.2024. Verfasst von Ruiying Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Cryptococcosis, Fungal Vaccines, Cryptococcus neoformans, Vaccines, Subunit. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The fungal infection, cryptococcosis, is responsible for >100,000 deaths annually. No licensed vaccines are available. We explored the efficacy and immune responses of subunit cryptococcal vaccines adjuvanted with Cationic Adjuvant Formulation 01 (CAF01). CAF01 promotes humoral and T helper (Th) 1 and Th17 immune responses and has been safely used in human vaccine trials. Four subcutaneous vaccines, each containing single recombinant Cryptococcus neoformans protein antigens, partially protected mice from experimental cryptococcosis. Protection increased, up to 100%, in mice that received bivalent and quadrivalent vaccine formulations. Vaccinated mice that received a pulmonary challenge with C . neoformans had an influx of leukocytes into the lung including robust numbers of polyfunctional CD4 + T cells which produced interferon gamma (IFNγ), tumor necrosis factor alpha (TNFα), and interleukin (IL)-17 upon ex vivo antigenic stimulation. Cytokine-producing lung CD8 + T cells were also found, albeit in lesser numbers. A significant, durable IFNγ response was observed in the lungs, spleen, and blood. Moreover, IFNγ secretion following ex vivo stimulation directly correlated with fungal control in the lungs. Thus, we have developed multivalent cryptococcal vaccines which protect mice from experimental cryptococcosis using an adjuvant which has been safely tested in humans. These preclinical studies suggest a path towards human cryptococcal vaccine trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States of America.
- Statens Serum Institut, Copenhagen, Denmark.
ORCID-Profile: Ruiying Wang, Lorena V N Oliveira, Charles A Specht, Stuart M Levitz
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Wang, R., Oliveira, L. V. N., Hester, M. M., Carlson, D., Christensen, D., Specht, C. A., & Levitz, S. M. (2024). Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines. PLOS Pathogens, 20(7), e1012220. https://doi.org/10.1371/journal.ppat.1012220
Vancouver
Wang R, Oliveira LVN, Hester MM, Carlson D, Christensen D, Specht CA, et al. Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines. PLOS Pathogens. 2024;20(7):e1012220. doi:10.1371/journal.ppat.1012220
BibTeX
@article{Wang2024,
author = {Wang, Ruiying and Oliveira, Lorena V N and Hester, Maureen M and Carlson, Diana and Christensen, Dennis and Specht, Charles A and Levitz, Stuart M},
title = {Protection against experimental cryptococcosis elicited by Cationic Adjuvant Formulation 01-adjuvanted subunit vaccines},
journal = {PLOS Pathogens},
year = {2024},
volume = {20},
number = {7},
pages = {e1012220},
doi = {10.1371/journal.ppat.1012220}
}
EUVIMED